Pseudomonas Aeruginosa Infection Treatment Market Report 2025

The pseudomonas aeruginosa infection treatment market size has grown strongly in recent years. It will grow from $2.45 billion in 2024 to $2.66 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to rising incidence of nosocomial infections, growing antibiotic resistance concerns, increased healthcare expenditure, expansion of hospital and healthcare facilities, focus on early diagnosis and intervention.

The pseudomonas aeruginosa infection treatment market size is expected to see strong growth in the next few years. It will grow to $3.68 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to increased research on antimicrobial peptides, focus on therapeutic efficacy and safety, rise in cases of multidrug-resistant paeruginosa, patient-centric approaches in treatment development, regulatory incentives. Major trends in the forecast period include combination therapies, advancements in drug delivery, point-of-care diagnostics, integration of genomic data in treatment strategies, global collaboration in antibiotic research.

The growth of the pseudomonas aeruginosa infection treatment market is anticipated to be driven by the increasing incidence of co-morbidities such as pneumonia, cystic fibrosis, urinary tract infection, and bloodstream infection. Comorbidities, which are concurrent medical conditions, often chronic, have a significant impact on both physical and mental health. As reported in August 2022 by the National Library of Medicine, the annual incidence rate of community-acquired pneumonia in the US is 24.8 instances per 10,000 adults, with increasing rates among the elderly. Pneumonia ranks as the eighth most common cause of death and the leading infectious cause of death, particularly affecting hospitalized patients in the intensive care unit. Thus, the rising prevalence of co-morbidities propels the pseudomonas aeruginosa infection treatment market.

The growth of the pseudomonas aeruginosa infection treatment market is poised to receive a boost from the increase in the geriatric population. The expanding elderly population, comprising individuals aged 65 and older, is characterized by heightened susceptibility to Pseudomonas Aeruginosa infections and unique healthcare requirements. According to a report from the World Health Organization (WHO) in October 2022, one in six people globally is expected to be 60 or older by 2030, and the worldwide population of individuals aged 60 and older is projected to reach 2.1 billion by 2050. The surge in the geriatric population underscores the demand for effective treatments within the Pseudomonas Aeruginosa Infection market.

Key players in the market for treating Pseudomonas aeruginosa infections are investing in personalized or targeted therapies, such as precision antibiotic treatments, to maintain their competitive edge. Precision antibiotic therapies involve targeted approaches that utilize engineered proteins, like bacteriocins, to specifically combat antibiotic-resistant bacteria. For example, in November 2023, Glox Therapeutics Ltd., a pharmaceutical company based in Scotland, secured $5.25 million (£4.3 million) in seed funding to develop precision antibiotic therapies aimed at antibiotic-resistant bacteria using bacteriocins - naturally occurring antimicrobial proteins. This funding will facilitate the establishment of laboratories in Oxford and Glasgow and enable the expansion of the research team. Glox's research is focused on targeting resistant Gram-negative pathogens such as Pseudomonas aeruginosa and Klebsiella pneumoniae, which are significant contributors to the global antimicrobial resistance crisis, resulting in 1.27 million deaths each year.

Strategic partnerships emerge as a prominent approach adopted by major companies in the pseudomonas aeruginosa infection treatment market. Shionogi & Co. Ltd. and the Global Antibiotic Research and Development Partnership (GARDP) collaborated with the Clinton Health Access Initiative (CHAI) to enhance antibiotic accessibility globally. This strategic partnership, reported in June 2023, aims to provide access to cefiderocol, an antibiotic designed for severe Gram-negative bacterial infections, addressing resistance challenges. The collaboration involves licensing agreements for the manufacturing and commercialization of cefiderocol, marking a significant step in altering antibiotic accessibility dynamics worldwide.

In March 2024, BiomX Ltd., a manufacturing company based in Israel, acquired Adaptive Phage Therapeutics for an undisclosed sum. The goal of this merger is to establish a leading phage therapy company with an advanced clinical pipeline focused on bacterial infections, particularly chronic pulmonary infections in patients with cystic fibrosis and diabetic foot osteomyelitis. Adaptive Phage Therapeutics is a US-based clinical-stage biotechnology firm that specializes in developing precision bacteriophage.

Major companies operating in the pseudomonas aeruginosa infection treatment market include AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co Inc., Janssen Pharmaceutica NV, Pfizer Inc., Lupin Limited, AstraZeneca plc, Bristol Myers Squibb Company, Gilead Sciences Inc., Novartis Pharmaceuticals Corporation, F. Hoffmann-La Roche AG, Bayer AG, Johnson & Johnson, Baxter International Inc., Neopharma LLC, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sandoz International GmbH, Dr. Reddy's Laboratories Ltd., Cipla Inc., Hikma Pharmaceuticals plc, Zydus Cadila Healthcare Limited, Wockhardt Ltd., Mayne Pharma Group Limited, Glenmark Pharmaceuticals Ltd., Perrigo Company plc, Amneal Pharmaceuticals LLC, Apotex Inc., Bausch Health Companies Inc., Biocon Ltd., Cadila Healthcare Ltd.

Europe was the largest region in the pseudomonas aeruginosa infection treatment market in 2024. North America is expected to be the fastest-growing region in the pseudomonas aeruginosa infection treatment market report during the forecast period. The regions covered in the pseudomonas aeruginosa infection treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pseudomonas aeruginosa infection treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pseudomonas aeruginosa is a gram-negative aerobic rod bacteria belonging to the pseudomonad family, commonly found in soil and water. It holds clinical significance in diagnostic labs and can be transmitted through breathing equipment, disinfectants, sinks, and patient-to-patient transfer.

The two primary types of medication used for treating Pseudomonas aeruginosa infections are monotherapy and combination therapy. Monotherapy involves using a single type of treatment, such as radiation therapy or surgery, for a specific disease or condition. Various drug classes are employed in the treatment of Pseudomonas aeruginosa infections, including aminoglycosides, cephalosporins, carbapenems, monobactams, and other classes. Administration of treatment for Pseudomonas aeruginosa can be through nasal, oral, and intravenous routes. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.

The pseudomonas aeruginosa infection treatment market research report is one of a series of new reports that provides pseudomonas aeruginosa infection treatment market statistics, including pseudomonas aeruginosa infection treatment industry global market size, regional shares, competitors with a pseudomonas aeruginosa infection treatment market share, detailed pseudomonas aeruginosa infection treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pseudomonas aeruginosa infection treatment industry. This pseudomonas aeruginosa infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pseudomonas aeruginosa market consists of sales of biofilm formation, motility (pili, flagella), pigment (pyocyanin), cytotoxins, phospholipases, elastases, and proteases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.